Printer Friendly

Chiron obtains United States patent.

Chiron Corporation (Emeryville, CA) has patented purified compounds comprising truncated insulin-like growth factor binding protein capable of binding to an antibody specific for the compound or to an insulin-like growth factor wherein the truncated insulin-like growth factor binding protein has a decreased affinity for insulin-like growth factors. Recombinant DNA molecules encoding the truncated insulin-like growth factor binding proteins are also described along with recombinant microorganisms and cell lines containing the DNA molecules and methods for producing the truncated insulin-like growth factor binding proteins using recombinant hosts containing the relevant DNA molecules. Methods for stimulating mitogenic activity and also for treating a bone disorder in mammals are also described. (US 6,391,588)
COPYRIGHT 2002 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Chiron obtains United States patent.(Brief Article)
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:May 1, 2002
Words:112
Previous Article:Avigen obtains United States patent.
Next Article:Nanogen and Bio-Rad sign licensing agreement.
Topics:


Related Articles
Chiron settles infringement suit against Gilead.
Chiron granted hepatitis C patent.
Chiron and Roche agree to major diagnostic licensing terms.
Chiron obtains United States patent.
Chiron grants non-exclusive HCV license to Pfizer.
Chiron announces settlement of patent dispute over tobramycin solution.
Genentech/Chiron patent litigation decision affirmed by CAFC.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |